Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FLT3 inhibitors induce p53 instability, driven by STAT5/MDM2/p53 competitive interactions in acute myeloid leukemia

4 Jan 2025

Abstract excerpt

FLT3 mutations are present in one third of patients with Acute myeloid leukemia (AML) and stand as an attractive therapeutic target. Although FLT3 inhibitors demonstrate clinical efficacy, the drug resistance remains challenging attributed to multiple mechanisms. In this study, we found that tyrosine kinase inhibitors (TKIs) targeting FLT3 prompt p53 degradation in AML cells with FLT3-ITD through ubiquitination....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Acute Myeloid Leukemia Research
Share to Chronic Myeloid Leukemia Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39756787
DOI: 10.1016/j.canlet.2025.217446

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FLT3 inhibitors induce p53 instability, driven by STAT5/MDM2/p53 competitive interactions in acute myeloid leukemiaPMID 39756787Read ↗

A combinatorial therapeutic approach to enhance FLT3-ITD AML treatment.Semantic proximity Read ↗

Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition with Quizartinib and Milademetan in FLT3 -ITD Mutant/ TP53 Wild-type Acute Myeloid LeukemiasSemantic proximity Read ↗

A unique role of p53 haploinsufficiency or loss in the development of acute myeloid leukemia with FLT3-ITD mutation.Semantic proximity Read ↗

Enhancing Therapeutic Efficacy of FLT3 Inhibitors with Combination Therapy for Treatment of Acute Myeloid Leukemia.Semantic proximity Read ↗

Momelotinib is a highly potent inhibitor of FLT3-mutant AMLSemantic proximity Read ↗

FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.Semantic proximity Read ↗

Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 through Mcl-1/Noxa axis.Semantic proximity Read ↗

A key role of the WEE1-CDK1 axis in mediating TKI-therapy resistance in FLT3-ITD positive acute myeloid leukemia patientsSemantic proximity Read ↗

STAT3 and p53: Dual Target for Cancer TherapySemantic proximity Read ↗

Persistent STAT5 activation in myeloid neoplasms recruits p53 into gene regulationSemantic proximity Read ↗

FLT3-ITD signals for CEBPA and p53 proteolysis by the ubiquitin-proteosome pathwaySemantic proximity Read ↗

FLT3-ITD signals for CEBPA and p53 proteolysis by the ubiquitin-proteosome pathwaySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.